Analyst Mark Massaro of BTIG reiterated a Buy rating on Guardant Health (GH – Research Report), retaining the price target of $50.00.
With more than 10 miles of Bay shoreline, a Redwood City Council study session focused on its vulnerability to sea-level rise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback